TROBICIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TROBICIN (TROBICIN).
Spectinomycin inhibits protein synthesis in susceptible bacteria by binding to the 30S ribosomal subunit, thereby blocking the initiation of peptide chain elongation.
| Metabolism | Primarily excreted unchanged in urine; minimal hepatic metabolism. |
| Excretion | Renal: >90% unchanged via glomerular filtration; biliary/fecal: <5%. |
| Half-life | 1.0-1.7 hours in normal renal function; prolonged to 10-24 hours in anuria; clinical context: dosing interval adjustment required in renal impairment. |
| Protein binding | Weakly bound (10-15%) to albumin. |
| Volume of Distribution | 0.20-0.25 L/kg; indicates distribution primarily into extracellular fluid. |
| Bioavailability | IM: 100% (complete absorption). |
| Onset of Action | IM: 1-2 hours (peak serum levels); IV: immediate (end of infusion). |
| Duration of Action | IM/IV: 8-12 hours (bactericidal levels); clinical note: single-dose therapy for uncomplicated gonorrhea. |
2 g intramuscularly as a single dose; for severe infections, 4 g intramuscularly as a single dose or 2 g intramuscularly every 12 hours for 2 days.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 10-50 mL/min: 2 g every 24-48 hours; CrCl <10 mL/min: 2 g every 48-72 hours. |
| Liver impairment | No specific adjustments recommended; use with caution in severe hepatic impairment. |
| Pediatric use | Children ≥2 years: 40 mg/kg intramuscularly as a single dose; maximum 2 g. For severe infections: 40 mg/kg intramuscularly every 12 hours for 2 days. |
| Geriatric use | Dose as for adults with normal renal function; monitor renal function and adjust if decreased CrCl. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TROBICIN (TROBICIN).
| Breastfeeding | Excreted in breast milk in low amounts; M/P ratio unknown. Consider risk vs benefit; discontinue nursing or drug based on importance to mother. |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; human data limited. Risk cannot be excluded; use only if clearly needed during all trimesters. |
| Fetal Monitoring | Monitor for hypersensitivity reactions, renal function, and hearing (if ototoxicity suspected). Fetal monitoring for growth and well-being if used in pregnancy. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to spectinomycin or any component of the formulation; neonates (due to benzyl alcohol content).
| Precautions | Not effective against syphilis; may mask or delay syphilis symptoms; use with caution in patients with renal impairment; allergic reactions including anaphylaxis reported; contains benzyl alcohol which may cause toxicity in neonates. |
Loading safety data…
| Fertility Effects | No known adverse effects on fertility in animal studies; human data insufficient. |